medigraphic.com
ISSN 1029-3035 (Electronic)

2021, Number 1

<< Back Next >>

Mediciego 2021; 27 (1)

Epidemiological and clinical characteristics in patients with nonvalvular atrial fibrillation

Solano-García S, Alberna-Cardoso A, Dornes-Ramón R, Springer-Toledo L, Baró-Rojas M, Hernández-Conde M

Language: Spanish
References: 22
Page: 1-16
PDF size: 604.07 Kb.


ABSTRACT

Introduction: atrial fibrillation is the arrhythmia that occurs most frequently in clinical practice, it is the cause of high hospitalization and requires adequate anticoagulant treatment.
Objective: to describe some of the demographic, epidemiological and clinical characteristics of patients with nonvalvular atrial fibrillation.
Methods: a cross-sectional study was carried out in patients admitted to the General Provincial Teaching Hospital of Ciego de Ávila during the three-year period January/2015-December/2017. The study included 194 patients who met the inclusion criteria. Data were collected from medical records. The CHA2DS2-VASc and HAS-BLED scales were used to assess thromboembolic and bleeding risk. The ethical principles were fulfilled.
Results: the male sex predominated (54.12 %), the age group between 51 and 75 years in both sexes (13.92 %, male and 11.86 %, female), arterial hypertension as a risk factor (73,20 %) and permanent atrial fibrillation as typology (67.53 %). Just over half had criteria for anticoagulation (55.67 %) and about a third (33.51%) had an increased risk of bleeding. Only 20.10 % had an anticoagulant prescription.
Conclusions: the male sex predominated, between 51 and 60 years old, with arterial hypertension as a risk factor and the permanent typology of atrial fibrillation, with criteria for anticoagulant treatment that had not prescribed it yet.


REFERENCES

  1. Fred M, Douglas P. Fibrilación auricular: manifestaciones clínicas, mecanismos y tratamiento. En: Mann DL, Zipes DP, Libby P, Bonow RO, editores. Braunwald Tratado de Cardiología. 10ma ed. Barcelona: Elsevier; 2016. p. 798-820.

  2. Guindo-Soldevila J, Martínez-Ruíz MD, Duran-Robert I, Tornos P, Martínez-Rubio A. Evaluación de riesgo tromboembólico y hemorrágico de los pacientes con fibrilación auricular. Rev Esp Cardiol [Internet]. 2013 [citado 19 Sep 2019];13 Supl C:9-13. Disponible en: https://www.revespcardiol.org/es-evaluacion-riesgo-tromboembolico-hemorragico-pacientes-articulo-S1131358713700530

  3. Guerra-García D, Valladares-Carvajal F, Bernal-Valladares EJ, Díaz-Quiñones JA. Factores de riesgo asociados a ictus cardioembólico en pacientes con fibrilación auricular no valvular. Rev. Finlay [Internet]. Mar 2018 [citado 19 Sep 2019];8(1):9-17. Disponible en: http://scielo.sld.cu/pdf/rf/v8n1/rf02108.pdf

  4. Grupo de Trabajo de la Sociedad Europea de Cardiología (ESC) para el diagnóstico y tratamiento de la fibrilación auricular. Guía ESC 2016 sobre el diagnóstico y tratamiento de la fibrilación auricular, desarrollada en colaboración con la EACTS. Rev Esp Cardiol [Internet]. 2017 [citado 12 Feb 2019];70(1):50.e1-e84. Disponible en: https://www.revespcardiol.org/index.php?p=revista&tipo=pdf-simple&pii=S0300893216306625

  5. January CT, Wann ML, Alpert JS, Calkins H, Cleveland JC, Clevenland JR, et al. AHA/ACC/HRS Guideline for the management of patients with atrial fibrilation. Circulat [Internet]. 2014 [citado 12 Mar 2019];130(23):e199-e267. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4676081/pdf/nihms615358.pdf

  6. Wysokinski WE, Cohoon KP, Melduni RM, Mazur M, Ammash N, Munger T, et al. Association between P-selectin levels and left atrial blood stasis in patients with nonvalvular atrial fibrillation. Thromb Res [Internet]. Dic 2018 [citado 12 Feb 2019];172:4-8. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6309447/pdf/nihms-996882.pdf

  7. Márquez MF, Gómez-Flores J, Aranda-Faustro A, Cazares-Campos I, Cárdenas M. Avances recientes en la fisiopatología de la fibrilación auricular. Arch. Cardiol. Mex. [Internet]. Dic 2009 [citado 12 Mar 2019];79 Supl 2:18-25. Disponible en: http://www.scielo.org.mx/pdf/acm/v79s2/v79s2a5.pdf

  8. Ministerio de Salud Pública (Cuba). Anuario Estadístico de Salud 2018 [Internet]. La Habana: Dirección Nacional de Registros Médicos y Estadísticas de Salud; 2019 [citado 12 May 2019]. Disponible en: http://files.sld.cu/bvscuba/files/2019/04/Anuario-Electr%C3%B3nico-Espa%C3%B1ol-2018-ed-2019-compressed.pdf

  9. Asociación Médica Mundial. Declaración de Helsinki de la AMM. Principios éticos para las investigaciones médicas en seres humanos. Ratificada en la 64ª Asamblea General, Fortaleza, Brasil, octubre 2013. Helsinki: 18ª Asamblea Mundial; 1964 [citado 30 Ene 2016]. Disponible en: http://www.anmat.gov.ar/comunicados/HELSINSKI_2013.pdf

  10. Ko D, Rahman F, Schnabel RB, Yin X, Benjamin EJ, Christophersen IE. Atrial fibrillation in women: epidemiology, pathophysiology, presentation, and prognosis. Nat Rev Cardiol [Internet]. Jun 2016 [citado 12 Mar 2019];13(6):321-32. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5579870/pdf/nihms866733.pdf

  11. Sharma M, Cornelius VR, Patel JP, Davies JG, Molokhia M. Efficacy and harms of direct oral anticoagulants in the elderly for stroke prevention in atrial fibrillation and secondary prevention of venous thromboembolism: systematic review and meta-analysis. Circulation [Internet]. Jul 2015 [citado 12 Abr 2019];132(3):194-204. Disponible en: https://www.ahajournals.org/doi/pdf/10.1161/CIRCULATIONAHA.114.013267

  12. Emdin CA, Wong CX, Hsiao AJ, Altman DG, Peters SA, Woodward M, et al. Atrial fibrillation as risk factor for cardiovascular disease and death in women compared with men: systematic review and meta-analysis of cohort studies. BMJ [Internet]. Ene 2016 [citado 12 Abr 2019];352:h7013. Disponible en: https://www.bmj.com/content/bmj/352/bmj.h7013.full.pdf

  13. Hobbs R, Taylor CJ, Jan Geersing G, Rutten FH, Brouwer JR, et al. European Primary Care Cardiovascular Society (EPCCS) consensus guidance on stroke prevention in atrial fibrillation (SPAF) in primary care. Eur J Prev Cardiol [Internet]. Mar 2016 [citado 12 Mar 2019];23(5):460-73. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4766963/pdf/10.1177_2047487315571890.pdf

  14. Tian XT, Xu YJ, Yang YQ. Gender differences in arrhythmias: focused on atrial fibrillation. J Cardiovasc Transl Res [Internet]. Feb 2020 [citado 14 Mar 2020];13(1):85-96. Disponible en: https://pubmed.ncbi.nlm.nih.gov/31637585/

  15. Grupo de Trabajo para el Manejo de la Fibrilación Auricular de la Sociedad Europea de Cardiología. Guías de práctica clínica para el manejo de la fibrilación auricular. Rev Esp Cardiol [Internet]. Dic 2010 [citado 12 Abr 2019];63(12):1483.e1-e83. Disponible en: http://www.comib.com/wp-content/uploads/2015/04/rcp2015/guias_de_fa.pdf

  16. Abraham NS, Singh S, Alexander GC, Heien H, Haas LR, Crown W, et al. Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study. BMJ [Internet]. Abr 2015 [citado 12 Abr 2019];350:h1857. Disponible en: https://www.researchgate.net/profile/William-Crown/publication/275723384_Comparative_risk_of_gastrointestinal_bleeding_with_dabigatran_rivaroxaban_and_warfarin_Population_based_cohort_study/links/554780060cf26a7bf4d90a7a/Comparative-risk-of-gastrointestinal-bleeding-with-dabigatran-rivaroxaban-and-warfarin-Population-based-cohort-study.pdf

  17. Goodman SG, Wojdyla DM, Piccini JP, White HD, Paolini JF, Nessel CC, et al. Factors associated with major bleeding events: insights from the ROCKETAF trial (rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation). J Am Coll Cardiol [Internet]. Mar 2014 [citado 12 Abr 2019];63(9):891-900. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4206565/pdf/nihms622088.pdf

  18. Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, Benjamin EJ, et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation [Internet]. Feb 2014 [citado 11 May 2019];129:837-47. Disponible en: https://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.929.7476&rep=rep1&type=pdf

  19. Cohen A, Dallongeville J, Durand-Zaleski I, Bouée S, Le Heuzey JY; EPHA Investigators. Characteristics and management of outpatients with history of or current atrial fibrillation: the observational French EPHA study. Arch Cardiovasc Dis [Internet]. Jul 2010 [citado 12 May 2019];103(6-7):376-87. Disponible en: https://www.sciencedirect.com/science/article/pii/S1875213610001294/pdfft?md5=5545c62b8a1cdfc633cdfb66ebe7804d&pid=1-s2.0-S1875213610001294-main.pdf

  20. Abed HS, Wittert GA, Leong DP, Shirazi MG, Bahrami B, Middeldorp ME, et al. Effect of weight reduction and cardiometabolic risk factor management on symptom burden and severity in patients with atrial fibrillation: a randomized clinical trial. JAMA [Internet]. 2013 [citado 12 May 2019];310(19):2050-60. Disponible en: https://jamanetwork.com/journals/jama/fullarticle/1779533

  21. Björck F, Renlund H, Lip GYH,Wester P, Svensson PJ, Själander A. Outcomes in a warfarin-treated population with atrial fibrillation. JAMA Cardiol [Internet]. May 2016 [citado 11 May 2019];1(2):172-80. Disponible en: https://jamanetwork.com/journals/jamacardiology/articlepdf/2515767/hoi160008.pdf

  22. Nielsen PB, Larsen TB, Skjoth F, Gorst-Rasmussen A, Rasmussen LH, Lip GY. Restarting anticoagulant treatment after intracranial hemorrhage in patients with atrial fibrillation and the impact on recurrent stroke, mortality, and bleeding: a nationwide cohort study. Circulation [Internet]. Ago 2015 [citado 12 Abr 2019];132(6):517-25. Disponible en: https://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.999.6148&rep=rep1&type=pdf




2020     |     www.medigraphic.com